

# INDEX

*Note:* Italicized letters *f* and *t* following page numbers indicate figures and tables, respectively.

- 4-6-20 Rule, 582
- Absorption, 100
- Accuracy, 573–575, 615*t*, 617–618
- Aconitine, 1557
- Actinium radionuclides, 918
  - See also radionuclides*
- Active (vector), 951
- Adenoviruses, 1152
  - gene therapy of, 1289
  - recombinant vectors, 1267–1268
- Adhesion formation, 536
- Adjuvants, 992–993
- ADMET, 100
- Adoptive transfer of *in vitro* transfected APCS, 991
- Adsorption, 390–391
- Aging, 435
- Aggregation, 386–387
- AIDS, 1534–1535
- Alphatoxin,
- Altered foci assay, 530
- Alzheimer's disease, 1125
- Amplification,
- Animal lectins, 135–136*t*
- Anti-drug antibody assay, 625–626
- Anti-HEV antibody, 526
- Anti-infectious agents, 139
- Anti-infectious diseases vaccines, 993
- Anti-inflammatory assay, 536
- Antibodies
  - anti-drug antibody assay, 625–626
  - anti-HEV antibody, 526
  - antibody arrays, 647
  - advantages and disadvantages of the most commonly used assays to detect binding anti-drug antibodies, 821–822*t*
  - delivery of, 869
  - FDA-approved antibody pharmaceuticals, 716–720*t*
  - monoclonal antibodies, 494, 496*t*
  - panning antibody libraries, 857
  - pathogens detected by recombinant antibodies, 863*t*
- Anticancer
  - activity, 139–140, 523
  - assay, 523
- Antiestrogen assay, 525
- Antimalarial activity assay, 556
- Antimalarial assay, 555
- Antiplatelet aggregation assay, 544
- Antisense, 976
- Antisense chemistries, 1064
- Antitubercular assay, 525

- Antitumor vaccines, 995–996
- Antivenoms, 692–693
- Antiviral assay, 524
- Arterial thrombosis assay, 545
- Arthritis, 1133
- Artificial cells, 1360–1370
- Artificial noses, 27
- Assays
- advantages and disadvantages of the
    - most commonly used assays to detect binding anti-drug antibodies, 821–822*t*
  - altered foci assay, 530
  - anti-drug antibody assay, 625–626
  - anti-inflammatory assay, 536
  - anticancer assay, 524
  - antiestrogen assay, 525
  - antimalarial activity assay, 556
  - antimalarial assay, 555
  - antiplatelet aggregation assay, 544
  - antitubercular assay, 525
  - antiviral assay, 524
  - binding assays, 821–822
  - blood pressure-related assay, 558
  - body weight-based liver tumor incidence assay, 530, 833
  - cerebral artery occlusion assay (MCAO), 558, 561
  - chloroquine assay, 557
  - dendritic cell assay, 546
  - ear edema assay, 544
  - estrogen assay, 551
  - fibrinolytic area assay, 546
  - fluorescent protein expression assay, 554
  - hepatoprotective assay, 530–531
  - IFN- $\gamma$  assay, 546
  - immunomodulating assay, 546
  - lymphoid organ assay, 548
  - neutralizing assays, 822
  - PBMC proliferation assay, 536
  - pulmonary hypertension assay, 558–559
  - radial assay of chemotaxis, 550
  - rat mast cell assay, 546
  - thread-induced thrombosis assay
  - thrombosis assay, 541–542
  - thrombolytic assay, 546
  - yeast oestrogen assay, 551–552
- Astatine radionuclides, 900
- See also radionuclides*
- Autoimmune diseases, 435, 1133
- Avian influenza, 1537–1538
- Baby hamster kidney (BHK), 11
- Baculovirus, 10–12
- B-Lactam, 34–35
- compounds, 34
- Binding assays, 919–922
- advantages and disadvantages of the most commonly used assays to detect binding anti-drug antibodies, 821*t*, 822
- Binding properties of antibodies, 926
- Biocatalysts, 37
- Biogenerics, 362–363
- Bioluminescence, 1306–1307
- Biomarker, 622–625
- Biosimilar products, 115–116
- CHMP guidelines concerning biosimilars, 1457
  - regulatory criteria, 115*t*, 1420–1422
- Biosynthetic pathways
- characterization of, 13, 15*t*, 19
- Biotechnology industry organization, 694
- Bismuth radionuclides, 919
- See also radionuclides*
- Blood pressure-related assay, 558–559
- Body weight-based liver tumor incidence assay, 530, 533
- Botulinum toxin, 1552–1553
- Bovine spongiform encephalopathy (BSE), 350
- Bromine radionuclides, 896
- See also radionuclides*
- Brucellosis, 1547
- Cancer, 1116, 1118–1120, 1122–1123, 1130–1131, 1133, 1137, 1140–1142, 1145–1146, 1149–1150, 1153, 1163, 1165–1168, 1170–1172, 1204, 1211, 1219, 1223, 1262, 1268–1272
- drugs, 1471–1473
- Cardiovascular diseases, 435
- Cardiovascular drugs, 1471, 1473
- Cationic dendrimers, 1027
- Cationic lipids, 1028–1029, 1031, 1075
- Cationic polymers, 1016, 1019, 1155
- Cavitation, 304–305
- Cell-based delivery of therapeutic genes, 949–950
- Cell penetrating peptides (CRPs), 1156–1157
- Cellular senescence and immortalization, 1362–1363
- Cerebral artery occlusion assay (MCAO), 561

- Chaperones, 5
- Chemokines, 1198–1214
- Chitosan, 130, 133, 140, 144
- Chloroquine assay, 557
- CHMP guidelines concerning biosimilars, 1458
- Cholera, 1539–1540
- Classification of vaccines, 1379*t*
- Claude, Albert, 973
- Clinical candidates, selection of 98, 102
- Collagens, 1035
- Combinatorial biosynthesis, 19–20
- Contaminant clearance, 337
- Convention on biological diversity (CBD), 1405–1406
- Copper radionuclides, 916–917  
*See also radionuclides*
- Copyright, 1395
- CYP, 1466–1468, 1476, 1478, 1467*t*  
CYP1, 1466  
CYP2, 1466  
CYP3, 1466  
CYP 2D6, 1466  
CYP 3A4, 1468
- Database and material deposit rights, 1395
- Deamidation, 372–375, 404–405
- Deamination, 380
- Delivery devices, 110–111, 401, 777
- Delivery of antibodies, 869
- Denaturation, 387–392, 394, 396, 399, 740–744
- Dendritic cell assay, 546
- Depurination, 378–379, 384
- Depyrimidation, 378–379, 384
- Diabetes, 435
- Direct encapsulation, 1031, 1033, 1037
- Disease targets for gene therapy, 953, 955*t*
- Distribution, 255
- DNA microarray genotyping, 1103
- DNA vaccines, 870–871, 1034, 1262
- Drug delivery vehicles, 750, 1150
- Drug receptors, 1464, 1471
- Drugs acting on the CNS, 1471, 1474
- Drugs involving growth factors, cytokines, and chemokines, 1211, 1212*t*
- Ear edema assay, 512, 536, 544
- Ebola hemorrhagic fever, 1525, 1533
- Electronic tongues, 27
- ELISA validation, 835, 845
- Embryonic stem cells, 1327–1330, 1335, 1348, 1369  
properties of, 1313, 1315
- Endocrine disruptors, 511, 523
- Endodermal differentiation, 1321
- Endosomal escape, 1042–1044
- Endotoxin removal, 36
- Escherichia coli, 3–6, 4*t*, 11–12, 30–31, 35, 60, 106, 296, 393, 445, 524, 673
- Estrogen assay, 551
- Ethnicity, 1477–1478
- Evaluation of homogeneity, 919
- Excipients, 392–393, 399*t*
- Excretion, 100
- Experimental joint pain, 1182
- Expiration of biologics patents, 1456*t*
- Expression-related functions, 976
- Extracellular limitations to nonviral gene delivery, 1019*t*
- Exubera, 400, 1213
- Fabry disease, 728
- Failure mode and effect, 346
- Fault tree analysis (FTA), 346
- FDA, 444, 320, 359, 400, 402, 450
- FDA-approved antibody pharmaceuticals, 716*t*
- FDA-approved enzyme pharmaceuticals, 725–727
- FDA-approved protein/peptide pharmaceuticals, 700–707*t*
- Fermentation, 332–333, 353*t*
- Fertility hormones, 710
- Fibrinolytic area assay, 546
- Filamentous fungi, 10
- First inhaled version of insulin (exubera), 1213  
*See also exubera and insulin*
- Fluorescence microscopy, 1302
- Fluorescent protein expression assay, 554
- Fluorine radionuclides, 898–900  
*See also radionuclides*
- Foldases, 5
- Food and Drug Administration (FDA), 320, 611
- Formulation, 108–113, 111*t*, 393
- Formulation of growth factors, cytokines, and chemokines, 1213*t*
- Fusarium, 511, 513  
mycotoxins, 513

- Gallium radionuclides, 915–916  
*See also radionuclides*
- Gantt chart for production scheduling of one batch of adenoviral vector, 1286*f*
- Gelsinger, Jesse, 966, 1399
- Gene amplification, 8
- Gene delivery targeting, 951
- Gene delivery vectors, 946–948, 947*t*
- Gene expression  
 control systems, 952  
 enhancement of, 18–19
- Gene-Gun, 991, 1005
- Gene therapy, 998–1002, 1262  
 in adenoviruses, 1264–1265  
 milestones, 1262*t*
- Genetic diseases, 1270–1271
- Genomics, 421
- Genotoxicity, 518
- Glycosylation, 819
- Gold standard, 94
- Growth regulatory hormones, 710–712
- Hematopoietic stem cells (HSCs), 1334–1339
- Hemophilia, 692
- Hepatitis A, 1551
- Hepatitis B, 994–995
- Hepatocyte primary culture, 595–596
- Hepatoprotective assay, 534–536
- Hepatotoxicity, 590
- Herpes simplex virus, 1153
- High-throughput screening for targets, 1117–1119
- Hirudin, 1227–1229, 1238
- Homeostatic hormones, 699
- Hormones  
 fertility hormones, 710  
 growth regulatory hormones, 710–712  
 homeostatic hormones, 699  
 immunomodulatory hormones, 712
- Human gene therapy (HGT), 943
- Human genome, 53–87  
 approaches to sequence, 69–73  
 mapping of, 65–68, 67*f*, 68*f*  
 human genome program (HGP), 55–57
- Human insulin, 386
- Huntington's disease, 1134
- Hyaluronic acid, 131
- Hybridization-based approaches, 1066
- Hybridization probes, 1090–1092
- Hydrodynamic degradation, 301, 304
- Hydrogels, 1036–1037
- Hydrolysis probes, 1090–1091
- IFN- $\gamma$  assay, 548–549
- Inflammation, 1214
- Imaging of gene transfer, 1297–1299
- Immortalization of human cells, 1361–1366
- Immune mechanisms, 817–818
- Immune tolerance, 818  
 of animals, 824
- Immune tolerant animals, 824
- Immunocamouflage, 500
- Immunodetection of pathogens, 861
- Immunogenicity, 444–448  
 of proteins, 745
- Immunomodulating assay, 546–547
- Immunomodulatory hormones, 712
- Impurities, 349
- Impurity clearance, 337–338
- Indium radionuclides, 908  
*See also radionuclides*
- Inhaled insulin, 763–764  
*See also insulin*
- Insect cell, 11
- Insulin, 393, 489  
 background, 759  
 first inhaled version of insulin (exubera), 1213  
 human insulin, 387  
 inhaled, 763  
 intranasal, 764  
 rapid-acting insulin, 762
- Intellectual property, 114
- Interchain disulphide bridges, 109
- Interferon, 778–783  
 background, 778  
 formulation, 781–783  
 pharmacokinetics in animals, 866  
 pharmacokinetics in humans, 868
- International Conference on harmonization (ICH), 321, 364, 395, 612
- Intracellular limitations, 1040  
 to nonviral gene delivery, 1019–1020*t*  
 toxicity of, 1041–1042
- Intranasal insulin, 764–765
- Intranasal siRNA injection, 1073
- Iodine radionuclides, 892  
*See also radionuclides*
- Ion-exchange separation of proteins, 602
- Ion channels, 1471
- Iraq, 1584

- Jenner, Edward, 692, 1602  
 “Junk” DNA, 82
- Labeling mabs and peptides, 892–896  
 Labeling with radiometals, 914–919  
 Lambda-based vectors, 57–61  
 Laser-induced Fluorescence (LIF), 480  
 Lead identification, 94–99  
   technologies, 95–96  
 Lead optimization, 100–104, 101*t*  
 Lead radionuclides, 918  
   *See also radionuclides*  
 Legionnaires disease (Legionellosis), 1546  
 Lentiviruses, 1153  
 Lipoplexes, 1158–1161  
 Liposomes, 455  
 Low-throughput screening for targets, 1116  
 Luciferase, 553  
 Lutetium radionuclides, 918  
   *See also radionuclides*  
 Lymphoid organ assay, 548
- MAbs, 494  
 Magnetic resonance imaging (MRI), 1299  
 Major functions of growth factors,  
   cytokines, and chemokines, 1200*t*  
 Malaria, 994  
 Mass spectrometry, 1510  
 Master cell bank, 959  
 Matrix-based delivery, 1031  
 Matrix-tethered delivery, 1037  
 Measurement of radiochemical purity,  
   (RCP), 921  
 Mesodermal differentiation, 1323  
 Metabolic shifts, 22  
 Metabolism, 94  
 Method transfer, 580  
 Microcystin toxicity, 516  
 Monoclonal antibodies, 494, 496*t*  
 Mononuclear phagocyte system (MPS), 129  
 MPS, 131  
 Mucosa surface, 145  
 Multidimensional liquid chromatography  
   of proteins, 603  
 Multidrug resistance (MDR), 141
- Nanocarriers for vascular drug delivery,  
   1151*f*  
 Nanoparticles, 454  
 Nanoparticulate drug carriers, 128  
 Narcoterrorism, 1610–1612  
 Natural polymers, 1037
- Nerve growth factor (NGF), 1174  
 Neurodegenerative diseases, 435  
 Neurological disorders, 1125  
 Neuropathic pain syndromes, 1174  
 Neutralizing assays, 822  
 NMR spectroscopy, 1505–1510  
 Nonlipidic polycation gene delivery  
   systems, 1155  
 Nonviral vectors, 948–949  
 Northern blotting, 1089  
 Norwalk, 1550–1551  
 Nuclear localization, 947  
 Nucleic acid delivery, 944
- Ocular disorders, 1134  
 Oligonucleotides, 243  
 Ovarian toxicity, 521–522  
 Oxygen mass transfer coefficient, 29
- p53, 1365*f*  
 Packaging of nucleic acids for therapy,  
   980–982
- Pancreatic islets, 454  
 Panning antibody libraries, 857  
 Parasite infections, 1124  
 Parkinson’s disease, 1117  
 Passive immunotherapy, 866  
 Passive targeting, 951  
 Pasteur, Louis, 692  
 Patent application, 1412–1413  
 Patent criteria, 1409–1411  
 Patent expiration of biologics, 1456*t*  
 Patent filing, 1413  
 Pathogens detected by recombinant  
   antibodies, 863*t*  
 PBMC proliferation assay, 602  
 PEGylated, 696, 706, 711–712, 726–730,  
   746, 748  
 Pegylation, 749–751, 754–755, 759, 764  
 Peroxisome proliferators activator receptor  
   (PPAR) agonists, 166  
 pH sensitivity, 281  
 Pharmaceutical production and  
   regulations, 1002–1004  
 Pharmacogenetics, 1464  
 Pharmacogenomics, 1465  
 Pharmacometabonomics, 1466  
 Pharmacophore, 97*t*, 98  
 Pharmacoproteomics, 1465  
 “Pharming”, 1434  
 Phase ½ trial, 963  
 Phase 2 trial, 963

- Physical scale-up parameters, 29  
Plague, 1545–1546  
Plant breeders' rights, 1395  
Plant-made pharmaceuticals (PMPs),  
1434–1447  
    threats posed, 1434–1437  
Plasmid DNA-based anti-tumor vaccines,  
995  
PLGA microspheres, 751  
Pluripotency, 1315–1319  
Polymerase chain reaction (PCR), 1089  
Polyplexes as cellular transfection agents,  
1025  
Positron emission tomography (PET),  
1307–1308  
Posttranslational gene silencing, 17  
Posttranslational modification, 11  
Powdermed gene-gun, 1005  
Poxviruses, 1152  
Precipitation, 386–387  
Precision, 574–575, 615*t*, 619–620, 627  
Preclinical biodistribution, 924–925  
Preclinical drug candidate safety  
    assessment, 1515–1517  
Prions, 693  
Process behavior  
    improvement of, 18–19  
Process characterization, 26–28  
Process optimization, 28–29  
Product potency tests, 962  
Product purification, 30–31  
Product recovery, 31–32  
Proteomics, 422, 501–502  
Pulmonary hypertension assay, 559–560  
Pulmozyme, 695  
  
QSAR, 97*t*, 98, 100  
Quality Issues, 37  
  
Radial assay of chemotaxis, 550–551  
Radiochemical purity (RCP), 921–923  
Radioisotopic imaging, 1304  
Radionuclides, 887–888*t*  
    actinium radionuclides, 918  
    astatine radionuclides, 900  
    bismuth radionuclides, 919  
    bromine radionuclides, 896–898  
    copper radionuclides, 916–918  
    for tumor imaging, 886–889  
    fluorine radionuclides, 898–900  
    gallium radionuclides, 915–916  
    iodine radionuclides, 892–896  
    indium radionuclides, 908–913  
    lead radionuclides, 941  
    lutetium radionuclides, 918  
    radionuclides suitable for labeling  
        biomolecules, 888*t*  
    rhenium radionuclides, 906–907  
    technetium radionuclides, 902–906  
    yttrium radionuclides, 913–915  
Rapid-acting insulin, 762–763  
    *See also insulin*  
Rat mast cell assay, 608–609  
Recognition of nucleic acids by immune  
    cells, 978  
Recombinant adenovirus vectors, 1267,  
1291–1294  
Recombinant expression systems, 3, 3*t*, 11,  
13, 39  
    characteristics of, 15*t*  
Red blood cells (RBCs), 452  
Reduced plasmid stability, 26  
Regulation of biotechnology products,  
1380  
Regulation of small molecules, 1377  
Regulatory criteria  
    biosimilar products, 115*t*  
Respiratory diseases, 720*t*, 1116, 1132  
Ricin, 1558, 1564, 1574–1575, 1579,  
1597–1598, 1618–1619, 1640, 1642, 1645  
Rift valley fever (RVF), 1549  
Risk assessment, 345–346  
Rhenium radionuclides, 906  
    *See also radionuclides*  
RNA interference RNAi, 1069  
    companies developing RNAi drugs,  
1120*t*  
    delivery of RNAi compounds, 1129  
    shRNA, 943, 945  
Robustness, 573, 580, 615, 622  
Routes of administration, 1066, 1214  
    of growth factors, cytokines, and  
    chemokines, 1199*t*  
RU486, 952  
  
Saccharomyces cerevisiae, 3, 7, 41, 48, 50,  
56  
Safety pharmacology, 103  
SARS, 1625, 1636  
SCID trial in France, 966  
Secreters, 11–12  
Secretion signal, 7  
Secretory expression systems, 5, 13  
Selected drug transporters, 1470*t*

- Selected drugs metabolized by various cytochrome P450, 1467*t*
- Selection of clinical candidates, 102, 111
- Selectivity, 576, 616–617, 626, 628, 630, 695
- Serial analysis of gene expression (SAGE), 1092
- Sialic acids, 133
- Single nucleotide polymorphisms (SNPs), 670
- Small interfering RNA (siRNA), 1013, 1016, 1146  
in clinical trials, 1076, 1162  
therapy, 1128
- Small-pox  
complex, 1600  
vaccine, 692
- Specificity, 573–574, 623*t*, 625–626, 641
- Stability, 495, 579
- Staphylococcal enterotoxin B (SEB), 1525, 1554
- StarLink Bt Corn, 1443, 1438–1439
- Stem cells, 1497–1514  
general classification, 1498–1500  
hematopoietic stem cells (HSCs), 1313, 1333
- Streptomyces, 139
- Structure-activity relationships, 1029, 1046
- Swine, 511, 526
- Syngenta Bt corn, 1433, 1440
- T-2 toxin, 1551–1552, 1554–1555
- Target product profile, 94
- Target selection, 89–90, 92
- TCDD, 511, 517, 520–521
- Technetium radionuclides, 883, 902  
*See also radionuclides*
- Telomerase, 1318
- Telomeres, 1362–1364
- Therapeutic proteins  
characteristics, 1222
- Thread-induced thrombosis assay, 545
- Thrombosis assay, 512, 545
- Thrombolytic assay, 512, 546
- Total error, 573, 578, 582, 584
- Toxicology, 103
- Toxicology and biodistribution of  
Ad5FGF-4, 956–969
- Trichothecene mycotoxins, 513–514
- Trade mark, 1396
- Trade related aspects of intellectual property rights (TRIPs), 1401, 1428
- Trade secret, 1394
- Transfer RNA (tRNA)  
“wobbling” of, 26
- Transmission electron microscopy (TEM), 1300
- Tuberculosis, 1525, 1548
- Tumor necrosis factor  $\alpha$  (TNF $\alpha$ ), 1117–1174, 1193
- Tumor targeting, 1052
- Twin arginine translocation (TAT), 6
- Urotoxicity, 511, 522
- Vaccination, 997
- Vaccine classification, 1549*t*
- Vaccine formulations, 1149–1157
- Vaccines  
active immunotherapy, 851, 870  
anti-infectious diseases vaccines, 993  
antitumor vaccines, 995–997  
classification, 1379*t*  
DNA vaccine, 871  
formulations, 1162–1163  
plasmid DNA-based anti-tumor vaccines, 995–997  
smallpox vaccine, 692  
subunit vaccines, 738–739
- Vasopressin, 709
- Vector construction, 958–959
- Vector decomplexation, 1044
- Vectors, 1263
- Viral clearance studies, 333–336
- Viral diseases, 1132–1133
- Viral infections, 1123–1124
- Virosomes, 1157–1158, 1158*f*
- Virus Removal, 36
- West-Nile encephalitis, 1536–1537
- Working cell bank, 959
- Yeasts, 6–10, 8*t*, 9*t*  
yeast cells as artificial chromosomes (YACs), 59–60, 61*f*, 63  
yeast display, 859–860  
yeast protein extraction, 1493
- Yeast oestrogen assay, 551–552
- Yellow fever, 1549–1550
- Yield, 697
- Yttrium radionuclides, 913  
*See also radionuclides*

